RxDoctor Payments Data

Jonathan Crane, DO

Dermatology · Wilmington, NCNPI 1134187594

Payments from drug & device makers

$21,783in general payments, 2019–2025

Across 481 payments — averaging $45.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$8K
  • AbbVie$3K
  • Johnson & Johnson$1K
  • Sun Pharmaceutical Industries Inc.$1K
  • UCB, Inc.$1K
  • Novartis$860
  • plus $6K from 26 others

What the payments were for

  • Food & beverage$13,40194%
  • Education$7826%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,783 in reported general payments places this provider in the 85th percentile of 475 dermatology providers in North Carolina.

See all dermatology providers in North Carolina

Medicare billing

Part B allowed, 2024
$382,600
Medicare patients
1,248
Services billed
7,857

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa20$421,522
OtezlaApremilast59$283,234
Dupixent PenDupilumab18$69,975
Metronidazole120$16,682
Tacrolimus188$14,885
Fluorouracil207$14,617
CiclopiroxCiclopirox Olamine593$10,130
Calcipotriene55$7,719
Ketoconazole580$7,577
Acitretin17$5,907
TazoracTazarotene11$5,188
Ciclopirox165$4,207
Azelaic Acid29$4,199
Doxycycline Monohydrate222$3,751
Tazarotene12$2,388

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$7,641$283,23459 claims
Almirall LLCTazorac$21$5,18811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 475 dermatology providers in North Carolina.

Other dermatology in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →